Plaque Psoriasis

This systematic review and meta-analysis of available randomized controlled trials compared biologics for psoriasis, such as ixekizumab, secukinumab, and ustekinumab.

In this analysis, investigators validated the Automatic Psoriasis Area and Severity Index (APASI), an AI-driven system for psoriasis severity assessment.

In this analysis, investigators highlight the impact of the route of MTX administration on drug survival among patients with psoriasis.

These data highlight secukinumab’s potential as a treatment to provide enhanced psychological outcomes among those with psoriasis.

This study highlighted tildrakizumab’s use in daily practice within a heterogeneous cohort of patients with psoriasis commonly affected by comorbid conditions.

Panelists discuss how plaque psoriasis affects 0.4% to 8% of the global population, with high-impact areas such as the scalp (up to 80% of patients) and nails (25% of patients) significantly impacting quality of life and warranting systemic therapy consideration.

This review of the month of September highlights some of the most significant dermatology headlines.

This review of Q3 developments in the dermatology space highlight a number of significant news stories from 2025.

During this EADV interview, Lebwohl speaks to some of the most recent developments in the psoriasis research space.

This EADV 2025 interview featuring Linda Stein Gold, MD, highlights her team’s findings on icotrokinra versus placebo and versus deucravacitinib in psoriasis.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New findings from the POSITIVE trial highlight tildrakizumab's effectiveness in enhancing quality of life for psoriatic disease patients.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

In this observational analysis, investigators highlight the potential causal link identified between NHHR and psoriasis development.